Non classé
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the launch of a new preclinical development targeting a strong anti microbial resistant bacteria, Klebsiella pneumonia